Nationwide Children's Hospital is a leading pediatric health care and research center in the United States, providing care for over one million patients annually. With 68 facilities across Ohio and beyond, the hospital offers a wide range of treatments, including specialized care in cardiology, oncology, gastroenterology, and neonatology. It is dedicated to serving all children, regardless of their family's financial situation, ensuring that quality health care is accessible to everyone. Families often travel from various regions, seeking advanced and often life-saving treatments that are not available elsewhere. Through its commitment to pediatric expertise and innovative research, Nationwide Children's Hospital aims to improve the health and well-being of children now and in the future.
Chief Financial and Administrative Officer and Executive Vice President
Chet Kaczor
Senior Vice President, Operations
Timothy Robinson
CEO
3 past transactions
Alcyone Therapeutics
Corporate Round in 2025
Alcyone Therapeutics is focused on developing advanced neural intervention technologies aimed at treating neurological conditions. The company utilizes an innovative combination of micro-fabrication techniques and biomedical engineering to create precision genetic therapies for central nervous system (CNS) disorders. Its core product offerings target drug therapies and address conditions such as hydrocephalus, ultimately aiming to enhance treatment options for patients suffering from chronic neuropathological issues. By pioneering next-generation therapies, Alcyone Therapeutics seeks to overcome existing challenges in CNS therapy development and unlock new possibilities for effective treatment.
Clarametyx Biosciences
Series A in 2024
Clarametyx Biosciences, Inc. is a biotechnology company based in Columbus, Ohio, focused on developing targeted and immune-enabling biologic therapies to address persistent infections linked to biofilms. Founded in 2020, the company utilizes a novel technology platform designed to penetrate the protective layers surrounding bacteria, facilitating immune responses and enhancing the effectiveness of antibiotic interventions. Among its key developments is CMTX-001, a humanized monoclonal antibody currently in preclinical stages aimed at treating hospital-acquired pneumonia. Clarametyx's innovative approach seeks to combat life-threatening infections while addressing the growing concerns of antibiotic resistance.
STAQ Pharma
Series C in 2022
STAQ Pharma, Inc. is a Denver-based company that specializes in manufacturing and selling compounded pharmaceutical medications. Founded in 2018, it operates a current Good Manufacturing Practice (cGMP) outsourcing facility that produces a range of compounded medications, including sterile solutions and prefilled syringes for hospital procedures. The company emphasizes safety, quality, and transparency in its offerings, providing healthcare facilities with reliable access to these critical products. STAQ Pharma sells its medications through its own pharmaceutical facilities and an online store, ensuring that inventory systems are in place to forecast needs and proactively supply partners with essential medications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.